The lymphedema treatment market is on the rise worldwide and is estimated to be worth USD 1623.55 million by 2029 from USD 1031.33 million in 2024. The global lymphedema treatment market is expected to grow at a decent CAGR of 9.50% during the forecast period.
Lymphedema is a chronic disease. According to an article published in the National Center for Biotechnology Information (NCBI), around 250 million people worldwide are suffering from lymphedema. The number of people suffering from lymphedema is expected to increase further in the coming years due to the growth in the aging population and the prevalence of cancer and propelling the demand for treatment options for lymphedema and driving the global market growth.
An increase in the aging population worldwide is contributing to the growth of the global lymphedema treatment market. The risk of cancer is high among older people. Surgeries and radiation therapies that are being used to treat cancer might result in the risk of lymphedema. Likewise, the incidence of cancer and lymphedema can be seen as being high among older people and the same factor is expected to contribute to the market growth. The WHO predicts the number of people aged 60 years and above will reach 2.1 billion by 2050, which was 1 billion in 2020.
Technological advancements are supporting the growth of the global lymphedema treatment market. The market participants have been investing significant funds in conducting R&D to develop innovative therapies to treat lymphedema, and this trend is likely to continue in the coming years and favor global market growth. Furthermore, rising awareness among people regarding lymphedema and treatment options, growing support, funding and policy initiatives from governments of various countries are promoting the market's growth rate.
On the other hand, poor awareness among people regarding lymphedema is a major obstacle to market growth. People's awareness levels of lymphedema have picked up in recent years. However, the awareness is still very limited and needs to be increased to a greater level. High costs associated with the treatment of lymphedema and poor reimbursement policies from healthcare payers for lymphedema are further limiting the market's growth rate. The scarcity of medical professionals who have specialization in lymphedema, limited availability of funding for the R&D around lymphedema and poor availability and accessibility of treatment options for lymphedema in some countries are inhibiting the growth rate of the global market.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2029 |
Base Year |
2023 |
Forecast Period |
2024 to 2029 |
Segments Covered |
By Product, Condition, Treatment, End User and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter's Five Forces Analysis; Competitive Landscape; Analyst Overview of Investment Opportunities |
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Market Leaders Profiled |
BSN medical, Tactile Medical, Bio Compression Systems, Inc., Lohmann & Rauscher |
The compression stockings segment accounted for the largest share of the global market in 2023 based on product. The compression stockings segment is estimated to register a healthy CAGR during the forecast period. Compression stockings are trusted as an effective method to treat lymphedema due to their ability to reduce swelling and improve lymphatic drainage, which is one of the major factors driving the growth of the compression stockings segment in the global market. Technological advancements in compression stockings and a growing number of older adults suffering from edema are further promoting the growth of the compression stockings segment in the worldwide market.The compression bandages segment occupied a considerable share of the worldwide market in 2023.The pneumatic compression devices segment is anticipated to register a notable CAGR in the worldwide market during the forecast period.
The cancer segment was the largest segment among all based on condition in the global lymphedema treatment market in 2023, and its domination is expected to continue throughout the forecast period. The growing cancer survival rates are one of the major factors propelling the growth of the cancer segment in the global market. The advancements in cancer diagnosis and treatments have been fuelling the number of cancer survivors worldwide and increasing the risk of developing lymphedema among cancer survivors, which is favoring segmental growth.
The compression therapy segment held the major share of the worldwide market in 2023 based on treatment options. The domination of the compression therapy segment in the global market is anticipated to continue during the forecast period due to increasing awareness of the benefits of compression therapy among medical professionals, technological advancements, and rising patient preference for home healthcare.
The hospital segment was the leader in the global market based on end-users in 2023. The lead of the hospital segment will continue during the forecast period. Hospitals do have strong referral networks from oncologists and specialists in lymphedema, which is one of the major factors propelling the segmental growth. In addition, factors such as the growing number of cancer patient visits to hospitals and growing awareness among medical professionals regarding the treatment options of lymphedema in hospital settings are further promoting the growth of the hospital segment in the worldwide market.The specialty clinics segment is expected to capture a considerable share of the worldwide market during the forecast period.
North America was the biggest regional segment in the worldwide market in 2023. The North American regional market is also estimated to do well in the global market and continue its supremacy during the forecast period. The prevalence of cancer-related lymphedema is high in North America and is the major factor driving the lymphedema treatment market growth in the North American region. The prevalence of breast cancer is highest in North America compared to all the other regions and people who suffer from breast cancer often also suffer from lymphedema. An estimated 1 in 8 people in the U.S. are likely to be diagnosed with breast cancer in the U.S., says the American Cancer Society. The North American region is equipped with advanced healthcare infrastructure and is providing effective care to lymphedema patients, this factor is supporting the regional market growth. Factors such as favorable reimbursement policies for lymphedema in North America and growing awareness among medical professionals regarding lymphedema are further contributing to the growth of the North America lymphedema treatment market.
The Asia-Pacific region accounted for the second-largest share of the global lymphedema treatment market in 2023 and is expected to witness a promising growth rate during the forecast period. The growing cancer patient population in the Asia-Pacific region and the rapid adoption of advanced medical technologies and therapies are driving the growth of the APAC market.
Europe is a notable regional market for lymphedema worldwide and is estimated to hold a considerable share of the global market during the forecast period. The aging population is growing at a considerable pace in the European region, which is expected to result in the growing demand for lymphedema treatment and propel the European market growth. People who are aged are most likely to develop conditions such as chronic diseases and are at risk of developing lymphedema. Rigorous R&D efforts around lymphedema treatment in Europe are another significant factor driving the European market growth.
Latin America is expected to grow at a steady growth rate in the global market during the forecast period.
The MEA region is anticipated to witness a moderate growth rate in the worldwide market in the coming years.
BSN medical, Tactile Medical, Bio Compression Systems, Inc., Lohmann & Rauscher, DePuy Synthes Companies (Johnson & Johnson), GAMMEX, Sigvaris, Arjo, DJO Global, BTL Industries, Lympha Press USA (Mego Afek), Biohorizons, Mölnlycke Health Care, McKim Medical, Jobst (3M Health Care), Acacia Pharma, Cardinal Health, Bio-Tissue (TissueTech, Inc.), Covidien (Medtronic) and CircAid Medical Products (medi USA) are some of the major players in the global lymphedema treatment market.
This research report on the global lymphedema treatment market has been segmented and sub-segmented based on product, condition, treatment, end-user and region.
By Product
By Condition
By Treatment
By End-User
By Region
Frequently Asked Questions
Factors driving market growth include an increase in surgical procedures leading to lymphedema, a rise in cancer cases (where lymphedema can be a side effect of treatment), and advancements in technology for more effective treatment options.
Challenges include limited awareness about lymphedema among the general population and healthcare professionals, high treatment costs, and accessibility issues in certain regions.
Regulatory concerns vary by region, but ensuring product safety, efficacy, and adherence to standards is a significant aspect for companies operating in this market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region